{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:07Z","timestamp":1792479127213,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011715","name":"Macmillan Cancer Support","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011715","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13096-7","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T03:04:29Z","timestamp":1730430269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cancer care treatment attrition in adults: Measurement approaches and inequities in patient dropout rates \u2013 a rapid review"],"prefix":"10.1186","volume":"24","author":[{"given":"Jenny","family":"Shand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Stovold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Goulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"13096_CR1","doi-asserted-by":"crossref","unstructured":"Health-Europe TLR. Reduce cancer inequity and inequality to reduce cancer mortality. Lancet Reg Health-Europe. 2023;25.","DOI":"10.1016\/j.lanepe.2023.100591"},{"issue":"1","key":"13096_CR2","first-page":"2819372","volume":"2017","author":"GK Singh","year":"2017","unstructured":"Singh GK, Jemal A. Socioeconomic and Racial\/Ethnic disparities in Cancer Mortality, incidence, and Survival in the United States, 1950\u20132014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017(1):2819372.","journal-title":"J Environ Public Health"},{"issue":"5","key":"13096_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/cncr.27854","volume":"119","author":"D Hui","year":"2013","unstructured":"Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer. 2013;119(5):1098\u2013105.","journal-title":"Cancer"},{"key":"13096_CR4","doi-asserted-by":"publisher","first-page":"e076335","DOI":"10.1136\/bmj-2023-076335","volume":"384","author":"C Garritty","year":"2024","unstructured":"Garritty C, Hamel C, Trivella M, Gartlehner G, Nussbaumer-Streit B, Devane D, et al. Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness. BMJ. 2024;384:e076335.","journal-title":"BMJ"},{"issue":"1","key":"13096_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"13096_CR6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"13096_CR7","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. https:\/\/www.ohrica\/programs\/clinical_epidemiology\/oxfordasp (accessed 02\/07\/2024)."},{"issue":"3","key":"13096_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00384-020-03778-6","volume":"36","author":"O Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman O, Koski S, Mulder K. Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. Int J Colorectal Dis. 2021;36(3):493\u20139.","journal-title":"Int J Colorectal Dis"},{"key":"13096_CR9","doi-asserted-by":"publisher","first-page":"175883592110598","DOI":"10.1177\/17588359211059874","volume":"13","author":"A Addeo","year":"2021","unstructured":"Addeo A, Hochmair M, Janzic U, Dudnik E, Charpidou A, Pluzanski A, et al. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Ther Adv Med Oncol. 2021;13:17588359211059874.","journal-title":"Ther Adv Med Oncol"},{"key":"13096_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.breast.2021.02.015","volume":"57","author":"D Basile","year":"2021","unstructured":"Basile D, Gerratana L, Corvaja C, Pelizzari G, Franceschin G, Bertoli E, et al. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study. Breast. 2021;57:104\u201312.","journal-title":"Breast"},{"issue":"3","key":"13096_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/cancers15030962","volume":"15","author":"MA Benda","year":"2023","unstructured":"Benda MA, Ulmer H, Weger R, Reimann P, Lang T, Pichler P, et al. Attrition rates in multiple myeloma treatment under Real World Conditions-An analysis from the Austrian Myeloma Registry (AMR). Cancers (Basel). 2023;15(3):962.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"13096_CR12","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.3390\/curroncol30090596","volume":"30","author":"DJ Boyne","year":"2023","unstructured":"Boyne DJ, Ngan E, Carbonell C, Wani RJ, Cirone Morris C, Martinez DJ, et al. Real-world study to Assess Patterns of Treatment Practices and clinical outcomes in metastatic colorectal Cancer patients with RAS Wild-Type Left-Sided tumours in Canada. Curr Oncol. 2023;30(9):8220\u201332.","journal-title":"Curr Oncol"},{"issue":"4","key":"13096_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/1754-9485.12887","volume":"63","author":"S Carruthers","year":"2019","unstructured":"Carruthers S, Pennefather M, Ward L, Giam K, Penniment M. Measuring (and narrowing) the gap: the experience with attendance of indigenous cancer patients for Radiation Therapy in the Northern Territory. J Med Imaging Radiat Oncol. 2019;63(4):510\u20136.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"13096_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10900-017-0382-z","volume":"43","author":"RW Dobbs","year":"2018","unstructured":"Dobbs RW, Malhotra NR, Caldwell BM, Rojas R, Moreira DM, Abern MR. Determinants of Clinic Absenteeism: a Novel Method of Examining Distance from Clinic and Transportation. J Community Health. 2018;43(1):19\u201326.","journal-title":"J Community Health"},{"key":"13096_CR15","doi-asserted-by":"publisher","first-page":"673901","DOI":"10.3389\/fonc.2021.673901","volume":"11","author":"D Fisch","year":"2021","unstructured":"Fisch D, Bozorgmehr F, Kazdal D, Kuon J, Klotz LV, Shah R, et al. Comprehensive dissection of treatment patterns and outcome for patients with metastatic large-cell neuroendocrine lung carcinoma. Front Oncol. 2021;11:673901.","journal-title":"Front Oncol"},{"issue":"1","key":"13096_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087.","journal-title":"BMC Cancer"},{"issue":"1","key":"13096_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/s12885-021-08420-4","volume":"21","author":"JY Fu","year":"2021","unstructured":"Fu JY, Zhang CP, Zhang ZY. Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer. BMC Cancer. 2021;21(1):663.","journal-title":"BMC Cancer"},{"issue":"14","key":"13096_CR18","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.3390\/cancers13143504","volume":"13","author":"SK Garattini","year":"2021","unstructured":"Garattini SK, Basile D, Bonotto M, Ongaro E, Porcu L, Corvaja C, et al. Drug holidays and overall survival of patients with metastatic colorectal Cancer. Cancers (Basel). 2021;13(14):3504.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"13096_CR19","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.esmoop.2024.102996","volume":"9","author":"MM Germani","year":"2024","unstructured":"Germani MM, Vetere G, Santamaria F, Intini R, Ghelardi F, Bensi M, et al. Treatment of patients with BRAF(V600E)-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open. 2024;9(4):102996.","journal-title":"ESMO Open"},{"issue":"8","key":"13096_CR20","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.3390\/curroncol29080460","volume":"29","author":"U Janzic","year":"2022","unstructured":"Janzic U, Turnsek N, Dediu M, Donev IS, Lupu R, Teodorescu G, et al. Real-World Testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-Mutated Advanced Non-small Cell Lung Cancer: a Retrospective Chart Review study (REFLECT). Curr Oncol. 2022;29(8):5833\u201345.","journal-title":"Curr Oncol"},{"issue":"11","key":"13096_CR21","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2022.2092852","volume":"63","author":"VH Jimenez-Zepeda","year":"2022","unstructured":"Jimenez-Zepeda VH, Chen G, Shaw E, Farris MS, Cowling T, Tay J. Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada. Leuk Lymphoma. 2022;63(11):2557\u201364.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"13096_CR22","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1245\/s10434-023-13469-5","volume":"30","author":"HH Kakish","year":"2023","unstructured":"Kakish HH, Ahmed FA, Pei E, Dong W, Elshami M, Ocuin LM, et al. Understanding factors leading to Surgical Attrition for Resectable Gastric Cancer. Ann Surg Oncol. 2023;30(7):4207\u201316.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"13096_CR23","doi-asserted-by":"publisher","first-page":"e748","DOI":"10.3747\/co.26.4861","volume":"26","author":"H Kennecke","year":"2019","unstructured":"Kennecke H, Berry S, Maroun J, Kavan P, Aucoin N, Couture F, et al. A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada. Curr Oncol. 2019;26(6):e748\u201354.","journal-title":"Curr Oncol"},{"issue":"8","key":"13096_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/jso.26638","volume":"124","author":"JP Kronenfeld","year":"2021","unstructured":"Kronenfeld JP, Collier AL, Turgeon MK, Ju M, Alterio R, Wang A, et al. Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: a United States Safety-Net collaborative analysis. J Surg Oncol. 2021;124(8):1317\u201328.","journal-title":"J Surg Oncol"},{"issue":"1","key":"13096_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s43046-019-0015-y","volume":"32","author":"N Kumar","year":"2020","unstructured":"Kumar N, Ray MD, Sharma DN, Pandey R, Lata K, Mishra A, et al. Vulvar cancer: surgical management and survival trends in a low resource setting. J Egypt Natl Canc Inst. 2020;32(1):4.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"28","key":"13096_CR26","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.2217\/fon-2022-0386","volume":"18","author":"S Lampaki","year":"2022","unstructured":"Lampaki S, Mountzios G, Georgoulias V, Rapti A, Xanthakis I, Baka S, et al. Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece. Future Oncol. 2022;18(28):3151\u201364.","journal-title":"Future Oncol"},{"issue":"6","key":"13096_CR27","first-page":"1529","volume":"11","author":"MPPS G","year":"2010","unstructured":"G MPPS. Patient and disease related factors associated with lost-to follow-up\/drop-outs of cervical cancer patients: a study at a major cancer hospital in South India. Asian Pac J Cancer Prev. 2010;11(6):1529\u201334.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"13096_CR28","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.esmoop.2022.100603","volume":"7","author":"E Martinelli","year":"2022","unstructured":"Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, et al. Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open. 2022;7(6):100603.","journal-title":"ESMO Open"},{"issue":"5","key":"13096_CR29","doi-asserted-by":"publisher","first-page":"e249417","DOI":"10.1001\/jamanetworkopen.2024.9417","volume":"7","author":"V Mathew Thomas","year":"2024","unstructured":"Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, et al. Treatment Patterns and Attrition with Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA Netw Open. 2024;7(5):e249417.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"13096_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41408-023-00883-x","volume":"13","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, et al. Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer J. 2023;13(1):111.","journal-title":"Blood Cancer J"},{"issue":"2","key":"13096_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.clcc.2015.10.003","volume":"15","author":"J McLean","year":"2016","unstructured":"McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, et al. Clinical practice patterns in Chemotherapeutic Treatment regimens for metastatic colorectal Cancer. Clin Colorectal Cancer. 2016;15(2):135\u201340.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"13096_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjh.19179","volume":"204","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Di Ciaccio P, Talaulikar D, Ku M, Ratnasingam S, et al. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: patterns of care and outcomes in a series from Australia and the United Kingdom. Br J Haematol. 2024;204(2):548\u201354.","journal-title":"Br J Haematol"},{"issue":"3","key":"13096_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bjh.18658","volume":"201","author":"S More","year":"2023","unstructured":"More S, Corvatta L, Manieri MV, Olivieri A, Offidani M. Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre. Br J Haematol. 2023;201(3):432\u201342.","journal-title":"Br J Haematol"},{"issue":"3","key":"13096_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40801-022-00302-w","volume":"9","author":"J Nieva","year":"2022","unstructured":"Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective analysis of real-World Management of EGFR-Mutated Advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and Survival Data. Drugs Real World Outcomes. 2022;9(3):333\u201345.","journal-title":"Drugs Real World Outcomes"},{"issue":"4","key":"13096_CR35","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/curroncol28040270","volume":"28","author":"DE O\u2019Sullivan","year":"2021","unstructured":"O\u2019Sullivan DE, Cheung WY, Syed IA, Moldaver D, Shanahan MK, Bebb DG, et al. Real-world treatment patterns, clinical outcomes, and Health Care Resource utilization in extensive-stage small cell Lung Cancer in Canada. Curr Oncol. 2021;28(4):3091\u2013103.","journal-title":"Curr Oncol"},{"issue":"10","key":"13096_CR36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00066-018-1318-y","volume":"194","author":"CH Rim","year":"2018","unstructured":"Rim CH, Yoon WS, Lee JA, Yang DS, Lee NK, Park YJ, et al. Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients. Strahlenther Onkol. 2018;194(10):894\u2013903.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"13096_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.clgc.2023.04.014","volume":"21","author":"U Swami","year":"2023","unstructured":"Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, et al. Treatment patterns, clinical outcomes, Health Care Resource utilization and costs in older patients with metastatic castration-resistant prostate Cancer in the United States: an analysis of SEER-Medicare Data. Clin Genitourin Cancer. 2023;21(5):517\u201329.","journal-title":"Clin Genitourin Cancer"},{"key":"13096_CR38","doi-asserted-by":"publisher","first-page":"979111","DOI":"10.3389\/fphar.2023.979111","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Yang J, Li Y, Zhang L, Li H, Wang J, et al. Treatment attrition rates and relevant risk factors in multiple myeloma: a real-world study in China. Front Pharmacol. 2023;14:979111.","journal-title":"Front Pharmacol"},{"issue":"3","key":"13096_CR39","doi-asserted-by":"publisher","first-page":"102047","DOI":"10.1016\/j.clgc.2024.01.019","volume":"22","author":"JC Tapia","year":"2024","unstructured":"Tapia JC, Bosma F, Gavira J, Sanchez S, Molina MA, Sanz-Beltran J, et al. Treatment patterns and survival outcomes before and after Access to Immune Checkpoint inhibitors for patients with metastatic urothelial carcinoma: a single-Center Retrospective Study from 2004 to 2021. Clin Genitourin Cancer. 2024;22(3):102047.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"13096_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/COC.0000000000000754","volume":"43","author":"ES Tsang","year":"2020","unstructured":"Tsang ES, Davies JM, Loree JM, Lim HJ, Renouf DJ, Gill S. Eligibility for second-line therapy in patients with Advanced Hepatocellular Carcinoma: a Population-based study. Am J Clin Oncol. 2020a;43(11):788\u201391.","journal-title":"Am J Clin Oncol"},{"issue":"39","key":"13096_CR41","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.3748\/wjg.v26.i39.6027","volume":"26","author":"ES Tsang","year":"2020","unstructured":"Tsang ES, Lim HJ, Renouf DJ, Davies JM, Loree JM, Gill S. Real-world treatment attrition rates in advanced esophagogastric cancer. World J Gastroenterol. 2020b;26(39):6027\u201336.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"13096_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2478\/raon-2022-0025","volume":"56","author":"N Turnsek","year":"2022","unstructured":"Turnsek N, Devjak R, Edelbaher N, Osrajnik I, Unk M, Vidovic D, et al. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study. Radiol Oncol. 2022;56(3):371\u20139.","journal-title":"Radiol Oncol"},{"issue":"4","key":"13096_CR43","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/hed.27327","volume":"45","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Lin B, Shen SY, Lin JL, Zhang TW, Yang HY. Factors associated with follow-up attendance of patients with oral squamous cell carcinoma: a retrospective cohort study. Head Neck. 2023;45(4):963\u201371.","journal-title":"Head Neck"},{"issue":"6","key":"13096_CR44","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/ecc.12312","volume":"24","author":"CM Chan","year":"2015","unstructured":"Chan CM, Wan Ahmad WA, Md Yusof M, Ho GF, Krupat E. Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer. Eur J Cancer Care (Engl). 2015;24(6):938\u201344.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"13096_CR45","doi-asserted-by":"publisher","first-page":"e006724","DOI":"10.1136\/bmjopen-2014-006724","volume":"5","author":"O Groene","year":"2015","unstructured":"Groene O, Crosby T, Hardwick RH, Riley S, Greenaway K, Cromwell D. A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer. BMJ Open. 2015;5(3):e006724.","journal-title":"BMJ Open"},{"issue":"6","key":"13096_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.clgc.2022.08.002","volume":"20","author":"AK Morgans","year":"2022","unstructured":"Morgans AK, Grewal S, Hepp Z, Fuldeore R, Odak S, Macahilig C, et al. Clinical and patient-reported outcomes of Advanced Urothelial Carcinoma following discontinuation of PD-1\/L1 inhibitor therapy. Clin Genitourin Cancer. 2022;20(6):543\u201352.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"13096_CR47","doi-asserted-by":"publisher","first-page":"e13143","DOI":"10.1111\/ecc.13143","volume":"28","author":"H Jensen","year":"2019","unstructured":"Jensen H, Moller H, Vedsted P. Characteristics of customary non-attenders in general practice who are diagnosed with cancer: a cross-sectional study in Denmark. Eur J Cancer Care (Engl). 2019;28(6):e13143.","journal-title":"Eur J Cancer Care (Engl)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13096-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13096-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13096-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:41:57Z","timestamp":1730436117000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13096-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13096"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13096-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1345"}}